Musculoskeletal disease Archives - Page 3 of 5

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

Article Type

Review

Published

15 Jan 2021

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Gian Luca Erre MD, PhD, Marco Sebastiani PhD, Andreina Manfredi MD, Elisabetta Gerratana MD, Fabiola Atzeni MD, Giuseppe Passiu MD, Arduino A Mangoni MD

Article Type

Review

Published

15 Jan 2021

This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.

Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country

Fernanda Gomes Gonçalves Chaer MD, Juliana Miranda de Lucena Valim MD, Rogério Castro Reis MD, Giselle Burlamaqui Klautau PhD, Branca Dias Batista de Souza MSc

Article Type

Original Research

Published

28 Jul 2020

This study evaluated the frequency of tuberculosis infection in patients with rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis after the use of biologic agents in a single center of rheumatology.

Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?

Louise Statham MPharm, PGClin Dip, PGCHE, IPresc, Sharon Abdy RN, BSc (Hons), Terry J Aspray MBBS, MD, FRCP, FRCP(Edinburgh)

Article Type

Original Research

Published

08 May 2020

The aim of this study was to analyse changes in C-terminal telopeptide on stopping long-term blood pressures in a real-world population to see whether
persistence of BP effect was maintained.

Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women

Santiago Palacios PhD, MD, Marieta Ramirez MD, Mariella Lilue MD

Article Type

Original Research

Published

23 Apr 2020

This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.